Guggenheim Starts ANI Pharmaceuticals (ANIP) at Buy

Guggenheim initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Buy rating and a price target of $65.00.

Analyst Louise Chen believes a sizable number of new product approvals over the next 12 to 18 months should drive the company's earnings growth to levels not reflected in the consensus number. In addition, she expects product acquisitions to accelerate following ANIP’s recent $144MM convertible debt offering.

For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.

Shares of ANI Pharmaceuticals closed at $54.28 yesterday.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Alphabet (GOOG) Tops Q1 EPS by 38c
• MarineMax (HZO) PT Lowered to $35 at Stifel